Kintara Therapeutics, based in Menlo Park, CA, is a dedicated biopharmaceutical company focused on the development of innovative cancer therapies for patients who have failed or become resistant to current treatment options.
With a strong emphasis on academic collaborations and clinical research institutions worldwide, Kintara Therapeutics aims to unlock the promise of biology in the battle against cancer. Their late-stage therapeutic, REM-001, is a second-generation photosensitizer drug that offers significant advantages over previous compounds, targeting solid tumor cancers with unmet medical needs.
Generated from the website